Nicotine Acetylcholine Receptors Modulate Bone Marrow-Derived Monocyte Differentiation

Stéphanie St‐Pierre,Patrick Roy,Wei Jiang,Camille Champigny,Alain R. Simard
DOI: https://doi.org/10.1016/j.jneuroim.2014.08.471
IF: 3.221
2014-01-01
Journal of Neuroimmunology
Abstract:It has recently been discovered that nicotine protects against Experimental Autoimmune Encephalomyelitis (EAE), a mouse model of Multiple Sclerosis (MS), by reducing disease severity, delaying disease onset and facilitating recovery. Previous data suggested that nicotine protects against EAE by inhibiting the production of monocytes and by inducing a shift in their phenotype, towards M2 (anti-inflammatory) rather than M1 (pro-inflammatory) monocytes/macrophages. Moreover, multiple nicotinic acetylcholine receptors (nAChRs) are involved in these processes. The goal of the present study was to determine if nicotine modulates the production and differentiation of bone marrow (BM)-derived monocytes. In this study, we first found that murine BM cells express multiple nAChRs, including the alpha6, alpha7 and alpha9 subunits. Using primary cultures of murine BM cells, we then determined the effect of nicotine on monocyte colony-stimulating factor (M-CSF) and interferon gamma (IFN gamma)-induced monocyte production and differentiation. This was achieved by assessing cell surface marker expression by flow cytometry. We found that nicotine inhibited the M-CSF + IFN gamma-induced increase in the expression of multiple M1 markers, suggesting that nicotine alters pro-inflammatory monocyte differentiation. This was then confirmed by measuring cytokine expression using enzyme-linked immunosorbent assays, where we found that nicotine inhibited the production of the pro-inflammatory cytokines tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and interleukin-12, while stimulating the secretion of interleukin-10, an anti-inflammatory cytokine. We therefore conclude that nicotine modulates BM-derived monocyte production and differentiation. The ultimate goal of this study is to develop a drug reducing inflammation in neurodegenerative diseases such as MS and Alzheimer's disease.
What problem does this paper attempt to address?